Came across this Co. while doing research on AVIR. They're a British manufacturer of drugs and vaccines, a fair range of products, pretty consistently profitable. They supply a flu vaccine to AVIR that seems to stand a good chance of FDA approval, which could be a major new earner. ADRs trade in NY at a little over $12, after steady decline. Common stock trades on London exchange. EPS is around $1.40, P/E is under 9.
Given the number of stocks in this price category with no earnings at all, or with astronomical losses, this would seem undervalued to me... or is there a skeleton in the closet that I'm not aware of?
Comments?
Steve Rogers |
